← United States · Coverage record
US · SEC FORM 4
Ocugen, Inc.
OCGN · Nasdaq · CIK 0001372299 · Healthcare · Biotechnology
INSIDER SIGNAL
1 qualifying P purchase group
in the current 180-day scoring window
5 Form 4 transaction lines observed in the same window
4 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
Purchase breadth & concentration
Roles in the peak window: Chief Financial Officer. Concentration uses priced qualifying P lines only and does not change the saved score.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-06-15 · Johnson-Greene Treerita Essalima.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 102,053,118
- Previous report
- 106,062,298
- Avg daily volume
- 7,472,502
- Days to cover
- 13.7
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-06-15 | Johnson-Greene Treerita Essalima | Purchase (P) | Common Stock | 21,000 | USD 1.23 | USD 25,830 | SEC filing ↗ |
| 2024-11-26 | Fernandes Prabhavathi | Purchase (P) | Common Stock | 10,000 | USD 0.91 | USD 9,100 | SEC filing ↗ |
| 2024-11-22 | Castillo Kirsten | Purchase (P) | Common Stock | 25,000 | USD 0.91 | USD 22,750 | SEC filing ↗ |
| 2023-06-14 | Zhang Junge | Purchase (P) | Common Stock | 200,278 | USD 0.50 | USD 100,139 | SEC filing ↗ |
| 2020-05-28 | Castillo Kirsten | Purchase (P) | Common Stock | 75,000 | USD 0.31 | USD 23,250 | SEC filing ↗ |
Form 4 evidence
10 transaction lines in the latest 365-day window; 148 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-09 | Musunuri Shankar | Sale (S) | Common Stock | 525,991 | USD 0.95 | USD 499,691 | SEC filing ↗ |
| 2026-09-09 | Musunuri Shankar | Sale (S) | Common Stock | 525,991 | USD 1.12 | USD 589,110 | SEC filing ↗ |
| 2026-06-15 | Johnson-Greene Treerita Essalima | Purchase (P) | Common Stock | 21,000 | USD 1.23 | USD 25,830 | SEC filing ↗ |
Show recent Form 4 evidence (6 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-10-09 | Musunuri Shankar | Sale (S) | Common Stock | 525,991 | USD 0.95 | USD 499,691 | SEC filing ↗ |
| 2026-09-09 | Musunuri Shankar | Sale (S) | Common Stock | 525,991 | USD 1.12 | USD 589,110 | SEC filing ↗ |
| 2026-06-15 | Johnson-Greene Treerita Essalima | Purchase (P) | Common Stock | 21,000 | USD 1.23 | USD 25,830 | SEC filing ↗ |
| 2026-04-01 | Zhang Junge | Option exercise / conversion (M) | Common Stock | 194,134 | USD 0.79 | USD 154,303 | SEC filing ↗ |
| 2026-01-02 | Ramachandran Ramesh | Award / grant (A) | Common Stock | 207,300 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-01-02 | Musunuri Shankar | Award / grant (A) | Common Stock | 3,123,201 | USD 0.00 | USD 0 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | OCGN |
| CIK | 0001372299 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 148 transaction lines from 2020-05-28 to 2026-10-09 5 P purchase lines · 68 S sale lines · 75 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.